Contribution of c-erbB-2 and topoisomerase IIα to chemoresistance in ovarian cancer

Cancer Research

Volumn 59, Issue 13, 1999, Pages 3206-3214

  Hengstler, Jan G ^a   Lange, Jost ^a   Kett, Alexandra ^a   Dornhöfer, Nadja ^a   Meinert, Rolf ^a   Arand, Michael ^a   Knapstein, Paul G ^a   Becker, Roger ^a   Oesch, Franz ^a   Tanner, Berno ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EMODIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MEDROXYPROGESTERONE ACETATE; NOVOBIOCIN; TAMOXIFEN; TREOSULFAN;

ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DISEASE MARKER; FEMALE; GENE OVEREXPRESSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; ONCOGENE C ERB; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL SURVIVAL; DNA PRIMERS; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-2; HUMANS; ISOENZYMES; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RNA, MESSENGER; SURVIVAL ANALYSIS; TIME FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0033168055     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Reese, D. M., and Slamon, D. J. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells, 15: 1-8, 1997.
2. Shih, C., Padhy, L. C., Murray, M., and Weinberg, R. A. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature (Lond.), 290: 261-264, 1981.
3. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell, 45: 649-657, 1986.
4. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J, Stuart, S. G., Udove, J., Ullrich, A., Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
5. Venter, D. J., Tuzi, N. L., Kumar, S., and Gullick, W. J. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet, 2: 69-72, 1987.
6. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
7. Meden, H., Marx, D., Roegglen, T., Schauer, A., and Kuhn, W. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int. J. Gynecol. Pathol., 17: 61-65, 1998.
8. Tanner, B., Kreutz, E., Weikel, W., Meinert, R., Oesch, F., Knapstein, P. G., and Becker, R. Prognostic significance of c-erB-2 mRNA in ovarian carcinoma. Gynecol. Oncol., 62: 268-277, 1996.
9. Meden, H., and Kuhn, W., Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur. J. Obstet. Gynecol. Reprod. Biol., 71: 173-179, 1997.
10. Hudziak, R. M., Schlessinger, J., and Ullrich, A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
11. Di-Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Washington DC), 237: 178-182, 1987.
12. Pietras, R. J., Arboleda, J., Reese, D. M., Wongvipat, N., Pegram, M. D., Ramos, L., Gorman, C. M., Parker, M. G., Sliwkowski, M. X., and Slamon, D. J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene, 10: 2435-2446, 1995.
13. Hancock, M. C., Langton, B. C. Chan, T., Toy P., Monahan, J. J., Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4575-4580, 1991.
14. Zhang, L., and Hung, M. C. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene, 12: 571-176, 1996.
15. Pegram, M D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., and Slamon, D. J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537-547, 1997.
16. Czernobilski, B. Blaustein's Pathology of the Female Genital Tract, pp. 560-607. New York: Springer, 1987.
17. Andreotti, P. E., Cree, I. A., Kurbacher, C. M., Hartmann, D. M., Linder, D., Harel, G., Gleiberman, I., Caruso, P. A., Ricks, S. H., Untch, M., Sartori, C., and Bruckner, H. W. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res., 55: 5276-5282, 1995.
18. Kurbacher, C. M., Cree, I. A., Bruckner, H. W., Brenne, U., Kurbacher, J. A., Muller, K., Ackermann, T., Gilster, T. J., Wilhelm, L. M., Engel, H., Mallmann, P. K., and Andreotti, P. E. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs, 9: 51-57, 1998.
19. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
20. Tanner, B., Hengstler, J. G., Laubscher, S., Meinert, R., Oesch, F., Weikel, W., Knapstein, P. G., and Becker, R. Mdm 2 mRNA expression is associated with survival in ovarian cancer. Int. J. Cancer. 74: 438-442, 1997.
21. Kraus, M. H., Popescu, N. C., Amsbaugh, S. C., and King, C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J., 6: 605-610, 1987.
22. Kalbfleisch, J. D., and Prentice, R. C. The Statistical Analysis of Failure Data. New York: Wiley, 1980.
23. Warenius, H. M., Seabra, L. A., and Maw, P. Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf-1 protein. Int. J. Cancer: 67: 224-231, 1996.
24. Sklar, M. D., and Prochownik, E. V. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res., 51: 2118-2123, 1991.
25. Van-Waardenburg, R. C., Meijer, C., Burger, H., Nooter, K., De-Vries, E. G., Mulder, N. H., and De-Jong, S. Effects of an inducible anti-sense c-myc gene transfer in a drug-resistant human small-cell-lung-carcinoma cell line. Int. J. Cancer, 73: 544-550, 1997.
26. Fan, J., Banerjee, D., Stambrook, P. J., and Bertino, J. R. Modulation of cytotoxicity of chemotherapeutic drugs by activated H-ras. Biochem. Pharmacol., 53: 1203-1209, 1997.
27. Isonishi, S., Hom, D. K., Thiebaut, F. B., Mann, S. C., Andrews, P. A., Basu, A., Lazo, J. S., Eastman, A., and Howell, S. B. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res., 51: 5903-5909, 1991.
28. Burt, R. K., Garfield, S., Johnson, K., and Thorgeirsson, S. S. Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR-1, glutathione-S-transferase-π and increased resistance to cytotoxic chemicals. Carcinogenesis (Lond.), 9: 2329-2332, 1988.
29. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R., Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., McKenzie, S., Yin, S., and Bast, R. C., Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087-4091, 1990.
30. Lee, K. F., Simon, H., Chen, H., Bates, B., Hung, M. C., and Hauser, C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature (Lond.), 378: 394-398, 1995.
31. Ullrich, A., and Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell, 61: 203-212, 1990.
32. Chazin, V. R., Kaleko, M., Miller, A. D., and Slamon, D. J. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene, 7: 1859-1866, 1992.
33. Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Forni, G., Nicoletti, I., Grignani, F., Pawson, T., and Pelicci, P. G. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell, 70: 93-104, 1992.
34. Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., and Weinberg, R. A. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature (Lond.), 363: 45-51, 1993.
35. Li, N., Batzer, A., Daly, R., Yajnik, V., Skolnik, E., Chardin, P., Bar-Sagi, D., Margolis, B., and Schlessinger, J. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature (Lond.), 363: 85-88, 1993.
36. Johnson, G. L., and Vaillancourt, R. R. Sequential protein kinase reactions controlling cell growth and differentiation. Curr. Opin. Cell. Biol., 6: 230-238, 1994.
37. Smith, K. A., Gorman, P. A., Stark, M. B., Groves, R. P., and Stark, G. R. Distinctive chromosomal structures are formed very early in the amplification of CAD genes in Syrian hamster cells. Cell, 63: 1219-1227, 1990.
38. Smith, K., Houlbrook, S., Greenall, M., Carmichael, J., and Harris, A. L. Topoisomerase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene, 8: 933-938, 1993.
39. Keith, W. N., Douglas, F., Wishart, G. C., McCallum, H. M., George, W. D., Kaye, S. B., and Brown, R. Co-amplification of erbB2, topoisomerase IIα and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur. J. Cancer, 29A: 1469-1475, 1993.
40. Eder, J. P., Jr., Chan, V. T-W., Ng, S-W., Rizvi, N. A., Zacharoulis, S., Teicher, B. A., and Schnipper, L. E. DNA topoisomerase II α expression is associated with alkylating agent resistance. Cancer Res., 55: 6109-6116, 1995.
41. De-Jong, S., Timmer-Bosscha, H., De-Vries, E. G., and Mulder, N. H. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line. Int. J. Cancer, 53: 110-117, 1993.
42. Hashimoto, S., Jing, Y., Kawazoe, N., Masuda, Y., Nakajo, S., Yoshida, T., Kuroiwa, Y., and Nakaya, K. Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk Res. 21: 875-883, 1997.
43. Barret, J. M., Calsou, P., Larsen, A. K., and Salles, B. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity. Mol. Pharmacol., 46: 431-346, 1994.
44. Ali-Osman, F., Berger, M. S., Rajagopal, S., Spence, A., and Livingston, R. B. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res., 53: 5663-5668, 1993.
45. Stevnsner, T., and Bohr, V. A. Studies on the role of topoisomerases in general, gene-and strand-specific DNA repair. Carcinogenesis (Lond.), 14: 1841-1850, 1993.
46. Barakat, R. R., Almadrones, L., Venkatraman, E. S., Aghajanian, C., Brown, C., Shapiro, F., Curtin, J. P., and Spriggs, D. A Phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol. Oncol., 69: 17-22, 1998.
47. Aziz, Z., Zahid, M., Ud Din Ahmed, Z., and Arshad, T. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer. Aust. N. Z. J. Med., 28: 403-409, 1998.